5.16
+0.18(+3.61%)
Currency In USD
| Previous Close | 4.98 |
| Open | 4.9 |
| Day High | 5.17 |
| Day Low | 4.71 |
| 52-Week High | 13.36 |
| 52-Week Low | 1.17 |
| Volume | 2.99M |
| Average Volume | 8.49M |
| Market Cap | 31.25M |
| PE | -0.43 |
| EPS | -11.9 |
| Moving Average 50 Days | 2.68 |
| Moving Average 200 Days | 3.75 |
| Change | 0.18 |
If you invested $1000 in BioXcel Therapeutics, Inc. (BTAI) since IPO date, it would be worth $29.24 as of August 26, 2025 at a share price of $5.16. Whereas If you bought $1000 worth of BioXcel Therapeutics, Inc. (BTAI) shares 5 years ago, it would be worth $8.25 as of August 26, 2025 at a share price of $5.16.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewswire Inc.
Aug 19, 2025 11:00 AM GMT
Data from more than 2,600 agitation episodes collected Topline data readout is on track for August NEW HAVEN, Conn., Aug. 19, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artifici
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewswire Inc.
Aug 18, 2025 11:00 AM GMT
Achieved alignment with the FDA on sNDA package to expand the IGALMI label for the At-Home (Outpatient) setting sNDA submission on track for Q1 2026 NEW HAVEN, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a bi
BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series
GlobeNewswire Inc.
Aug 13, 2025 11:00 AM GMT
NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D